Loading…
Gossamer Bio, Inc. is projected to rise to $0.2184 by 2027, a +29% move from its current price of $0.1695. GOSS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.156 | $0.1696 | $0.1842 | +0.04% |
| Aug 6 | $0.1508 | $0.1696 | $0.1908 | +0.07% |
| Aug 7 | $0.1469 | $0.1697 | $0.1959 | +0.11% |
| Aug 8 | $0.1438 | $0.1697 | $0.2004 | +0.14% |
| Aug 9 | $0.141 | $0.1698 | $0.2045 | +0.18% |
| Aug 10 | $0.1386 | $0.1699 | $0.2082 | +0.21% |
| Aug 11 | $0.1364 | $0.1699 | $0.2117 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.1364 | $0.1699 | $0.2117 | +0.25% |
| Week 2 | $0.1248 | $0.1703 | $0.2324 | +0.50% |
| Week 3 | $0.1167 | $0.1708 | $0.2499 | +0.75% |
| Week 4 | $0.1103 | $0.1712 | $0.2657 | +1.00% |
| Week 5 | $0.105 | $0.1716 | $0.2806 | +1.25% |
| Week 6 | $0.1004 | $0.1721 | $0.2948 | +1.51% |
| Week 7 | $0.0964 | $0.1725 | $0.3085 | +1.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. Its GB002 program is an inhaled, small molecule inhibitor of PDGFR, colony-stimulatin factor 1 receptor and c-KIT, which is in Phase 3 clinical trials for PAH.
Gossamer Bio has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
The current price of Gossamer Bio, Inc. (GOSS) is $0.1783. Its market capitalization stands at $87.16M and the stock is ranked 4001 by market cap. The asset is categorized in the Healthcare sector.
The near-term price outlook shows a neutral stance for 2026 with an avg price of $0.1783, a min of $0.136, and a max of $0.2481. The forecast then shifts to a bullish trajectory in the following years, with 2027 avg $0.2237 and 2030 avg $0.3025, extending through 2050 with an avg of $0.9302 and a max of $2.14.
A major floor 41.0% below — a decisive break under it would weaken the trend.
The nearest floor, 19.8% below — buyers have tended to step in here.
The nearest ceiling, 22.1% above — a clean break opens room to run.
A major ceiling 166.1% above — clearing it would confirm fresh momentum.
Key GOSS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GOSS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.1918 | Sell | $0.1793 | Sell |
| MA 10 | $0.1679 | Buy | $0.1746 | Sell |
| MA 20 | $0.1677 | Buy | $0.1717 | Sell |
| MA 50 | $0.1759 | Sell | $0.223 | Sell |
| MA 100 | $0.276 | Sell | $0.4886 | Sell |
| MA 200 | $1.39 | Sell | $0.9392 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.60 | Neutral |
| Stoch RSI (14) | 56.68 | Neutral |
| CCI (20) | 8.94 | Neutral |
| Williams %R (14) | -52.11 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.94 | Buy |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 47.89 | Neutral |
| TRIX (15) | -0.42 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 58.04 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 0.20 | Sell |
| ADX (14) | 17.99 | Neutral |
| ATR (14) | 0.01 | Info |
Technical picture for the past 30 days shows bullish sentiment overall. The RSI(14) is 50, suggesting a neutral momentum near the halfway point. The 50-day simple moving average (SMA50) is $0.1765, while the 200-day simple moving average (SMA200) sits at $1.40, indicating a potential longer-term average below recent prices.
The stock’s immediate support is reported at $0.136 and resistance at $0.207. Over the last 30 days, the price has traded in a range from a low of $0.1017 to a high of $0.3126, illustrating notable near-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.136 | $0.1695 | $0.2348 | 0% | Neutral | |
| $0.1591 | $0.2184 | $0.324 | +29% | Bullish | |
| $0.1962 | $0.2864 | $0.4533 | +69% | Bullish | |
| $0.1803 | $0.2774 | $0.4613 | +64% | Bullish | |
| $0.183 | $0.2951 | $0.511 | +74% | Bullish | |
| $0.1765 | $0.2975 | $0.5335 | +76% | Bullish | |
| $0.1362 | $0.2395 | $0.4429 | +41% | Bullish | |
| $0.15 | $0.2747 | $0.5222 | +62% | Bullish | |
| $0.179 | $0.3411 | $0.6649 | +101% | Bullish | |
| $0.205 | $0.406 | $0.8099 | +140% | Bullish | |
| $0.172 | $0.3823 | $0.8384 | +126% | Bullish | |
| $0.4223 | $0.9384 | $2.16 | +454% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.136 | $0.1695 | $0.1948 | +0.00% |
| September 2026 | $0.1365 | $0.166 | $0.2107 | -2.07% |
| October 2026 | $0.142 | $0.1751 | $0.2267 | +5.48% |
| November 2026 | $0.1358 | $0.1693 | $0.2228 | -3.28% |
| December 2026 | $0.1396 | $0.1759 | $0.2348 | +3.87% |
Click any year to see its month-by-month GOSS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GOSS price prediction for 2026 points to an average of $0.1695 (low $0.136, high $0.2348) — a potential gain of 0% on today's $0.1695. A consolidation phase looks the most probable path here.
In 2027, GOSS is projected to trade between $0.1591 and $0.324, averaging $0.2184 — a potential gain of +29% from today's $0.1695. That is up +29% on the projected 2026 average. Momentum favours further upside here.
Gossamer Bio, Inc.'s 2028 outlook centres on $0.2864, within a $0.1962 to $0.4533 range. That is up +31% on the projected 2027 average. That marks a +69% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, GOSS could reach as high as $0.4613, with a base case around $0.2774 and support toward $0.1803 — roughly +64% from $0.1695. Momentum favours further upside here.
Expect GOSS to range from $0.183 to $0.511 through 2030. The $0.2951 average target implies a +74% move from current prices. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The GOSS price prediction for 2031 points to an average of $0.2975 (low $0.1765, high $0.5335) — a potential gain of +76% on today's $0.1695. Momentum favours further upside here.
In 2032, GOSS is projected to trade between $0.1362 and $0.4429, averaging $0.2395 — a potential gain of +41% from today's $0.1695. That is -19% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Gossamer Bio, Inc.'s 2033 outlook centres on $0.2747, within a $0.15 to $0.5222 range. That is up +15% on the projected 2032 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2034, GOSS could reach as high as $0.6649, with a base case around $0.3411 and support toward $0.179 — roughly +101% from $0.1695. Buyers look set to stay in control over this stretch.
Expect GOSS to range from $0.205 to $0.8099 through 2035. The $0.406 average target implies a +140% move from current prices. That is up +19% on the projected 2034 average. Momentum favours further upside here.
The GOSS price prediction for 2040 points to an average of $0.3823 (low $0.172, high $0.8384) — a potential gain of +126% on today's $0.1695. Buyers look set to stay in control over this stretch.
In 2050, GOSS is projected to trade between $0.4223 and $2.16, averaging $0.9384 — a potential gain of +454% from today's $0.1695. That is up +145% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GOSS today (≈ 5,899.705015 GOSS) could be worth
$5,536.28
+$4,536.28 (+454%) by 2050 · US Dollar
Based on the average projected GOSS price of $0.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GOSSwould be worth at today's price.
$1,000 invested in GOSS on Jul 31, 2025 (≈ 490.196088 GOSS) would be worth
$83.09
-$916.91 (-91.7%) today · 0.08× · US Dollar
Based on a GOSS entry price of $2.04 vs. today's $0.1695.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.136 | $1,246.32 | +24.6% |
| 1 month ago | $0.168 | $1,008.93 | +0.9% |
| 3 months ago | $0.37 | $458.11 | -54.2% |
| 6 months ago | $2.48 | $68.35 | -93.2% |
| 1 year ago | $2.04 | $83.09 | -91.7% |
| All time (5.0y) ago | $8.29 | $20.45 | -98.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GOSS forecast.
Our base-case forecast reaches $0.34 around 2034.
Implied market cap at $0.34: $166.21M
The multi-year forecast shows a bullish trajectory beyond 2026. For 2027 the avg price is $0.2237 with ROI 25.5% and bullish sentiment, followed by 2028 with avg $0.2904 and ROI 62.9%, and 2029 with avg $0.2862 and ROI 60.5%. In 2030 the avg price is $0.3025 with ROI 69.7% and bullish sentiment, and 2031 shows avg $0.3016 with ROI 69.1%.
By 2032 the avg falls to $0.2442 (ROI 37%), then to $0.2748 in 2033 (ROI 54.1%), and rises again in 2034 to $0.3362 (ROI 88.5%), with 2035 at $0.4055 (ROI 127.4%). The forecast continues bullish into 2040, with avg $0.3709 and ROI 108%, and culminates in 2050 with avg $0.9302 and ROI 421.7% (max $2.14).
These are estimates, not guarantees. The forecast indicates a generally bullish path, but actual results will depend on factors beyond the data provided, including market dynamics and company-specific developments.
Tap a question to reveal the answer.
The 2030 forecast lists min $0.1875, avg $0.3025, max $0.5239, with ROI 69.7% and sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROIs, including ROI of 25.5% in 2027, 69.7% in 2030, and 421.7% in 2050, though 2026 is neutral.
Yes—the 2030 max is $0.5239, which exceeds $0.50.
Current price is $0.1783 and market cap is $87.16M.
2035 is forecast as BULLISH.
Gossamer Bio, Inc. Community Discussion
0Share your Gossamer Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.